TRCT
MNPR icon

Tower Research Capital (TRC)’s Monopar Therapeutics MNPR Stock Holding History

Tower Research Capital (TRC)’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$41.7K Buy
761
+414
+119% +$25K ﹤0.01% 2906
2025
Q4 		$22.7K Sell
347
-205
-37% -$16.8K ﹤0.01% 3009
2025
Q3 		$45.1K Buy
+552
New +$24.7K ﹤0.01% 2609
2025
Q2 		– Sell
-303
Closed -$11K – 5453
2025
Q1 		$11K Sell
303
-393
-56% -$14.2K ﹤0.01% 3580
2024
Q4 		$15.3K Buy
+696
New +$11.7K ﹤0.01% 3412
2024
Q3 		– Sell
-1,584
Closed -$5.78K – 5887
2024
Q2 		$5.78K Buy
1,584
+13
+0.8% +$46 ﹤0.01% 4654
2024
Q1 		$5.35K Buy
1,571
+847
+117% +$2.52K ﹤0.01% 4552
2023
Q4 		$1.23K Sell
724
-21
-3% -$43 ﹤0.01% 5413
2023
Q3 		$2.31K Sell
745
-2
-0.3% -$7 ﹤0.01% 5172
2023
Q2 		$3.19K Buy
747
+604
+422% +$3.09K ﹤0.01% 5099
2023
Q1 		$1K Sell
143
-423
-75% -$6.26K ﹤0.01% 5576
2022
Q4 		$7K Sell
566
-60
-10% -$732 ﹤0.01% 4588
2022
Q3 		$5K Buy
626
+152
+32% +$1.44K ﹤0.01% 5154
2022
Q2 		$5K Sell
474
-238
-33% -$2.69K ﹤0.01% 5076
2022
Q1 		$9K Buy
712
+232
+48% +$3.43K ﹤0.01% 4469
2021
Q4 		$8K Buy
+480
New +$10.6K ﹤0.01% 4804
2021
Q2 		– Sell
-442
Closed -$14K – 5697
2021
Q1 		$14K Buy
442
+161
+57% +$5.88K ﹤0.01% 4154
2020
Q4 		$9K Sell
281
-659
-70% -$17K ﹤0.01% 4389
2020
Q3 		$25K Buy
+940
New +$30.4K ﹤0.01% 3791
2020
Q2 		– Sell
-14
Closed – – 4887
2020
Q1 		$0 Buy
+14
New +$877 ﹤0.01% 3564

Other funds holding MNPR

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Tower Research Capital (TRC)'s MNPR Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Monopar Therapeutics (MNPR) stake by 119% in Q1 2026, buying an estimated $25K and bringing the position to 761 shares worth $41.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2906.

Tower Research Capital (TRC) first reported a position in MNPR in Q1 2020 and has held it in 20 quarters since. The position peaked at $45.1K in Q3 2025. 82 funds tracked by Wall St. Rank hold MNPR as of Q1 2026.

  • Tower Research Capital (TRC) held 761 shares of Monopar Therapeutics worth $41.7K as of Q1 2026.
  • Tower Research Capital (TRC) bought 414 Monopar Therapeutics shares in Q1 2026, an estimated $25K.
  • Monopar Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #2906 holding.
  • Tower Research Capital (TRC) first reported a position in Monopar Therapeutics in Q1 2020 and has held it in 20 quarters since.
  • Tower Research Capital (TRC)'s Monopar Therapeutics position peaked at $45.1K in Q3 2025.
  • 82 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.